The DOI matches its Crossref record; 405 of the 405 references it cites were found in a registry or an index.
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Open accessAbstract
Cyclin-dependent kinases (CDK/Cyclins) form a family of heterodimeric kinases that play central roles in regulation of cell cycle progression, transcription and other major biological processes including neuronal differentiation and metabolism. Constitutive or deregulated hyperactivity of these kinases due to amplification, overexpression or mutation of cyclins or CDK, contributes to proliferation of cancer cells, and aberrant activity of these kinases has been reported in a wide variety of human cancers. These kinases therefore constitute biomarkers of proliferation and attractive pharmacological targets for development of anticancer therapeutics. The structural features of several of these kinases have been elucidated and their molecular mechanisms of regulation characterized in depth, providing clues for development of drugs and inhibitors to disrupt their function. However, like most other kinases, they constitute a challenging class of therapeutic targets due to their highly conserved structural features and ATP-binding pocket. Notwithstanding, several classes of inhibitors have been discovered from natural sources, and small molecule derivatives have been synthesized through rational, structure-guided approaches or identified in high throughput screens. The larger part of these inhibitors target ATP pockets, but a growing number of peptides targeting protein/protein interfaces are being proposed, and a small number of compounds targeting allosteric sites have been reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 405
Cyclins and their partners: from a simple idea to complicated reality.
Hunt, T. (1991) · PubMed · Cited by 156
Wong, A. S. L., Lee, R. H. K., Cheung, A. Y., Yeung, P. K. K., Chung, S. K., Cheung, Z. H., & Ip, N. Y. (2011) · Nature Cell Biology · doi:10.1038/ncb2217 · Cited by 155
Akiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., & Akinaga, S. (1997) · PubMed · Cited by 152
Leshchenko, V. V., Kuo, P.-Y., Shaknovich, R., Yang, D. T., Gellen, T. A., Petrich, A. M., Yu, Y., Remache, Y. K., Weniger, M. A., Rafiq, S., et al. (2010) · Blood · doi:10.1182/blood-2009-12-257485 · Cited by 152
Lee, D. K., Duan, H. O., & Chang, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002285200 · Cited by 152
Meredith, S. D., Levine, P. A., Burns, J. A., et al. (1995) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1995.01890070076016 · Cited by 151
CDK inhibition and cancer therapy
Garrett, M. D., & Fattaey, A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80015-x · Cited by 151
Ou, C.-Y., Poon, V. Y., Maeder, C. I., Watanabe, S., Lehrman, E. K., Fu, A. K. Y., Park, M., Fu, W., Jørgensen, E. M., Ip, N. Y., et al. (2010) · Cell · doi:10.1016/j.cell.2010.04.011 · Cited by 151
Wu, S. C., & Zhang, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240515 · Cited by 150
Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics
Fischer, P. M., & Lane, D. P. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003374048 · Cited by 149
Mikolčević, P., Sigl, R., Rauch, V., Hess, M. W., Pfaller, K., Barišić, M., Pelliniemi, L. J., Boesl, M. R., & Geley, S. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06261-11 · Cited by 145
Santo, L., Vallet, S., Hideshima, T., Cirstea, D. D., Ikeda, H., Pozzi, S., Patel, K. J., Okawa, Y., Görgün, G., Perrone, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.510 · Cited by 145
A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.
Lane, M. E., Yu, B., Rice, A. G., Lipson, K. E., Liang, C., Sun, L., Tang, C., McMahon, G., Pestell, R. G., & Wadler, S. (2001) · PubMed · Cited by 145
Erlanson, M., Portin, C., Linderholm, B. K., Lindh, J., Roos, G., & Landberg, G. (1998) · Blood · doi:10.1182/blood.v92.3.770 · Cited by 144
Glab, N., Labidi, B., Qin, L., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01035-8 · Cited by 144
Chen, H.-H., Wang, Y.-C., & Fann, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2736-2745.2006 · Cited by 144
Fu, A. K. Y., Fu, W., Ng, A. K. Y., Chien, W. W. Y., Ng, Y.-P., Wang, J. H.-C., & Ip, N. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307606100 · Cited by 143
Guo, W., Lonardo, F., Ueda, T., Kim, T. K., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<199::aid-ijc7>3.0.co;2-4 · Cited by 140
Shukla, V., Zheng, Y., Mishra, S. K., Amin, N. D., Steiner, J. P., Grant, P. G., Kesavapany, S., & Pant, H. C. (2012) · The FASEB Journal · doi:10.1096/fj.12-217497 · Cited by 139
Peptide aptamers as guides for small-molecule drug discovery
Baines, I., & Colas, P. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.007 · Cited by 138
Wang, D., de la Fuente, C., Deng, L., Wang, L., Zilberman, I., Eadie, C., Healey, M., Stein, D., Denny, T. N., Harrison, L. E., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.16.7266-7279.2001 · Cited by 137
Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5.
Brion, J., & Couck, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 136
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression
Bellail, A. C., Olson, J. J., & Hao, C. (2014) · Nature Communications · doi:10.1038/ncomms5234 · Cited by 135
Byth, K. F., Thomas, A. P., Hughes, G. D., Forder, C. L., McGregor, A., Geh, C., Oakes, S. E., Green, C., Walker, M., Newcombe, N. J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0836 · Cited by 135
Xu, W., Wang, Z., Zhang, W., Qian, K., Li, H., Kong, D., Li, Y., & Tang, Y.-C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.008 · Cited by 134
Néant, I., & Guerrier, P. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90121-8 · Cited by 134
High cyclin B1 expression is associated with poor survival in breast cancer
Aaltonen, K., Amini, R., Heikkilä, P., Aittomäki, K., Tamminen, A., Nevanlinna, H. A., & BLOMQVIST, C. P. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604874 · Cited by 134
Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases
Gadbois, D. M., Hamaguchi, J. R., Swank, R. A., et al. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91160-r · Cited by 134
Yuan, J., Krämer, A., Matthess, Y., Yan, R., Spänkuch, B., Gätje, R., Knecht, R., Kaufmann, M., & Strebhardt, K. (2005) · Oncogene · doi:10.1038/sj.onc.1209202 · Cited by 131
Feldmann, G., Mishra, A., Bisht, S., Karikari, C. A., Garrido‐Laguna, I., Rasheed, Z. A., Ottenhof, N. A., Dadon, T., Alvarez, H., Fendrich, V., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.7.16475 · Cited by 130
O'Hare, M. J., Kushwaha, N., Zhang, Y., Aleyasin, H., Callaghan, S. M., Slack, R. S., Albert, P. R., Vincent, I. J., & Park, D. S. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2899-05.2005 · Cited by 129
A non-covalent peptide-based carrier for in vivo delivery of DNA mimics
Morris, M. C., Gros, E., Aldrian, G., Choob, M. V., Archdeacon, J., Heitz, F., & Divita, G. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm053 · Cited by 129
Self-citationIn vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Joshi, K., Rathos, M. J., Joshi, R., Sivakumar, M., Mascarenhas, M., Kamble, S., Lal, B., & Sharma, S. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0613 · Cited by 129
Progression through the G1‐phase of the on‐going cell cycle
Boonstra, J. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10617 · Cited by 128
Chu, X., DePinto, W., Bartkovitz, D., So, S., Vu, B. T., Packman, K. E., Lukacs, C., Ding, Q., Jiang, N., Wang, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606138 · Cited by 128
CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression
Liang, Q. Y., Li, L., Zhang, J., Yang, L., Wang, L., Liu, D., Feng, J., Hou, P., Yao, R., Zhang, Y., et al. (2013) · Scientific Reports · doi:10.1038/srep02932 · Cited by 127
Emanuel, S. L., Rugg, C. A., Gruninger, R. H., Lin, R., Fuentes‐Pesquera, A. R., Connolly, P. J., Wetter, S. K., Hollister, B. A., Kruger, W. W., Napier, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0882 · Cited by 127
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation
Burd, C. J., Petre, C. E., Morey, L. M., Wang, Y., Revelo, M. P., Haiman, C. A., Lu, S., Fenoglio‐Preiser, C. M., Li, J., Knudsen, E. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506281103 · Cited by 125
Cheng, S.-W. G., Kuzyk, M. A., Moradian, A., Ichu, T.-A., Chang, V. C.-D., Tien, J. F., Vollett, S. E., Griffith, M., Marra, M. A., & Morin, G. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06267-11 · Cited by 124
Trimurtulu, G., Faulkner, D. J., Perry, N. B., Ettouati, L., Litaudon, M., Blunt, J. W., Munro, M. H. G., & Jameson, G. B. (1994) · Tetrahedron · doi:10.1016/s0040-4020(01)89674-5 · Cited by 122
Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas
Kitahara, K., Yasui, W., Kuniyasu, H., Yokozaki, H., Akama, Y., Yunotani, S., Hisatsugu, T., & Tahara, E. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620107 · Cited by 121
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol
Androic, I., Krämer, A., Yan, R., Rödel, F., Gätje, R., Kaufmann, M., Strebhardt, K., & Yuan, J. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-391 · Cited by 121
Bettayeb, K., Tirado, Ò. M., Marionneau‐Lambot, S., Ferandin, Y., Lozach, O., Morris, J. C., Mateo‐Lozano, S., Drueckes, P., Schächtele, C., Kubbutat, M. H. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1826 · Cited by 121
CDK8 Maintains Tumor Dedifferentiation and Embryonic Stem Cell Pluripotency
Adler, A. S., McCleland, M. L., Truong, T., Lau, S., Modrusan, Z. D., Soukup, T. M., Roose‐Girma, M., Blackwood, E. M., & Firestein, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3886 · Cited by 121
Gius, D. R., Ezhevsky, S. A., Becker‐Hapak, M., Nagahara, H., Wei, M. C., & Dowdy, S. F. (1999) · PubMed · Cited by 116
Cyclin‐dependent kinase 9–cyclin K functions in the replication stress response
Yu, D. S., Zhao, R., Hsu, E., Cayer, J., Ye, F., Guo, Y. P., Shyr, Y., & Cortez, D. (2010) · EMBO Reports · doi:10.1038/embor.2010.153 · Cited by 116
The cyclin box fold: protein recognition in cell-cycle and transcription control
Noble, M. E. M., Endicott, J., Brown, N. R., & Johnson, L. N. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01144-4 · Cited by 115
Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Smalley, K. S. M., Contractor, R., Nguyen, T. K., Xiao, M., Edwards, R. H., Muthusamy, V., King, A. J., Flaherty, K. T., Bosenberg, M., Herlyn, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0235 · Cited by 115
Cell Cycle and Biochemical Effects of PD 0183812
Fry, D. W., Bedford, D. C., Harvey, P. H., Fritsch, A., Keller, P. R., Wu, Z., Dobrusin, E. M., Leopold, W. R., Fattaey, A., & Garrett, M. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008867200 · Cited by 112
Chen, Y.-J., Dominguez‐Brauer, C., Wang, Z., Asara, J. M., Costa, R. H., Tyner, A. L., Lau, L. F., & Raychaudhuri, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.007997 · Cited by 111
Chao, Y., Shih, Y., Chiu, J., Chau, G. Y., Lui, W., Yang, W. K., Lee, S., & Huang, T. (1998) · PubMed · Cited by 110
Extraneuronal roles of cyclin‐dependent kinase 5
Rosales, J. L., & Lee, K. (2006) · BioEssays · doi:10.1002/bies.20473 · Cited by 110
Firestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E. F., Giovannucci, E. L., Hahn, W. C., Fuchs, C. S., & Ogino, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24908 · Cited by 109
A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
Menu, E., García, J., Huang, X., Liberto, M. D., Toogood, P. L., Chen, I., Vanderkerken, K., & Chen‐Kiang, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6404 · Cited by 108
Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr02 · Cited by 106
A Melanoma Molecular Disease Model
Vidwans, S. J., Flaherty, K. T., Fisher, D. E., Tenenbaum, J. M., Travers, M., & Shrager, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018257 · Cited by 106
DePinto, W., Chu, X., Yin, X., Smith, M., Packman, K. E., Goelzer, P., Lovey, A. J., Chen, Y., Qian, H., Hamid, R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0355 · Cited by 106
Cyclin-dependent Kinase 5 Promotes Insulin Exocytosis
Lilja, L., Yang, S. N., Webb, D., Juntti‐Berggren, L., Berggren, P., & Bark, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103776200 · Cited by 104
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor
Suzuki, T., Urano, T., Miki, Y., Moriya, T., Akahira, J., Ishida, T., Horie, K., Inoue, S., & Sasano, H. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00444.x · Cited by 104
Smith, D. S., Greer, P. L., & Tsai, L. (2001) · PubMed · Cited by 104
Clinical anticancer drug development: targeting the cyclin-dependent kinases
Benson, C., Kaye, S. B., Workman, P., Garrett, M. D., Walton, M., & Bono, J. S. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602229 · Cited by 103
Update on the molecular biology of mantle cell lymphoma
Bertoni, F., Rinaldi, A., Zucca, E., & Cavalli, F. (2006) · Hematological Oncology · doi:10.1002/hon.767 · Cited by 103
Cyclin-dependent Kinase 5 (Cdk5) Activation Domain of Neuronal Cdk5 Activator
Tang, D., Chun, A. C. S., Zhang, M., & Wang, J. H.-C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.19.12318 · Cited by 102
Sundaram, J. R., Poore, C. P., Sulaimee, N. H. B., Pareek, T. K., Asad, A. B. M. A., Rajkumar, R., Cheong, W. F., Wenk, M. R., Dawe, G. S., Chuang, K., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3593-12.2013 · Cited by 101
Going out of the brain: Non-nervous system physiological and pathological functions of Cdk5
Contreras-Vallejos, E., Utreras, E., & González-Billault, C. E. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.022 · Cited by 100
Peptide inhibitors of protein kinases—discovery, characterisation and use
Bogoyevitch, M. A., Barr, R. K., & Ketterman, A. J. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.025 · Cited by 99
Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4
Soni, R., O'Reilly, T., Furet, P., Muller, L., Stephan, C., Zumstein-Mecker, S., Fretz, H., Fabbro, D., & Chaudhuri, B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.6.436 · Cited by 98
Zheng, Y., Amin, N. D., Hu, Y., Rudrabhatla, P., Shukla, V., Kanungo, J., Kesavapany, S., Grant, P. G., Albers, W., & Pant, H. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134643 · Cited by 97
Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex
Zhang, J., Li, H., Yabut, O., Fitzpatrick, H., D'Arcangelo, G., & Herrup, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5628-09.2010 · Cited by 96
Chilosi, M., Doglioni, C., Yan, Z., Lestani, M., Menestrina, F., Sorio, C., Benedetti, A., Vinante, F., Pizzolo, G., & Inghirami, G. (1998) · Europe PMC (PubMed Central) · Cited by 96
Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
Comstock, C. E. S., Augello, M. A., Benito, R. P., Karch, J. M., Tran, T. H., Utama, F. E., Tindall, E. A., Wang, Y., Burd, C. J., Groh, E. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2865 · Cited by 95
Millar, E. K. A., Dean, J. L., McNeil, C. M., O’Toole, S. A., Henshall, S. M., Tran, T. H., Lin, J., Quong, A. A., Comstock, C. E. S., Witkiewicz, A. K., et al. (2009) · Oncogene · doi:10.1038/onc.2009.13 · Cited by 94
Targeting cyclin-dependent kinases in anti-neoplastic therapy
Bruyère, C., & Meijer, L. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.08.004 · Cited by 92
Zheng, Y., Li, B., Amin, N. D., Albers, W., & Pant, H. C. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03133.x · Cited by 91
Nakayama, H., Okumura, S., Daisaki, H., Kato, Y., Uehara, H., Adachi, S., Yoshimura, M., & Okada, M. (2010) · Cancer · doi:10.1002/cncr.25244 · Cited by 91
Park, M., Watanabe, S., Poon, V. Y., Ou, C.-Y., Jørgensen, E. M., & Shen, K. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.002 · Cited by 91
Leung, W. K. C., Ching, A. K.-K., Chan, A. W. H., Poon, T. C. W., Mian, H., Wong, A. S. T., To, K., & Wong, N. (2011) · Oncogene · doi:10.1038/onc.2011.161 · Cited by 90
Mahadevan, D., Plummer, R., Squires, M. S., Rensvold, D., Kurtin, S. E., Pretzinger, C., Dragovich, T., Adams, J., Lock, V., Smith, D.-M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq734 · Cited by 90
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome
Guen, V. J., Gamble, C., Flajolet, M., Unger, S., Thollet, A., Ferandin, Y., Superti‐Furga, A., Cohen, P. A., Meijer, L., & Colas, P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306814110 · Cited by 89
Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen, I. T., Akamatsu, M., Smith, M., Lung, F. T., Duba, D. E., Roller, P. P., Fornace, A. J., & O'Connor, P. M. (1996) · PubMed · Cited by 88
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions
Georgieva, J. V., Sinha, P., & Schadendorf, D. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.3.229 · Cited by 87
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
Walsby, E. J., Pratt, G., Shao, H., Abbas, A. Y., Fischer, P. M., Bradshaw, T. D., Brennan, P., Fegan, C., Wang, S., & Pepper, C. J. (2013) · Oncotarget · doi:10.18632/oncotarget.1568 · Cited by 86
Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors
Payton, M. N., Chung, G., Yakowec, P. S., Wong, A., Powers, D., Xiong, L., Zhang, N., Martínez-Leal, J. F., Bush, T. L., Santora, V. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2507 · Cited by 86
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.
Bonfanti, M., Taverna, S., Salmona, M., D’Incalci, M., & Broggini, M. (1997) · PubMed · Cited by 85
Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK·Cyclin Complexes
Marais, A., Ji, Z., Child, E. S., Krause, E., Mann, D. J., & Sharrocks, A. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154005 · Cited by 84
CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing
Chen, H.-H., Wong, Y., Genevière, A., & Fann, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.049 · Cited by 83
p35 nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease
Nakamura, S., Kawamoto, Y., Nakano, S., Akiguchi, I., & Kimura, J. (1997) · Acta Neuropathologica · doi:10.1007/s004010050687 · Cited by 82
Zheng, D., Cho, Y., Lau, A. T. Y., Zhang, J., Ma, W.-Y., Bode, A. M., & Dong, Z. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1137 · Cited by 82
Eggers, J. P., Grandgenett, P. M., Collisson, E. C., Lewallen, M. E., Tremayne, J. R., Singh, P. K., Swanson, B. J., Andersen, J. M., Caffrey, T. C., High, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2288 · Cited by 81
Dysregulation of CDK8 and Cyclin C in tumorigenesis
Xu, W., & Ji, J. (2011) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2011.09.002 · Cited by 80
Reddy, M. V. R., Akula, B., Cosenza, S. C., Divakar, S. K. A., Mallireddigari, M. R., Pallela, V. R., Billa, V. K., Subbaiah, D. R. C. V., Bharathi, E. V., Carpio, R. V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401073p · Cited by 80
Uchida, T., Ishiguro, K., Ohnuma, J., Takamatsu, M., Yonekura, S., & Imahori, K. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01163-x · Cited by 80
Different expression patterns of cyclins A, D1 and E in human colorectal cancer
Wang, A., Yoshimi, N., Suzui, M., Yamauchi, A., Tarao, M., & Mori, H. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01226270 · Cited by 79
Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators
Tang, D., & Wang, J. H.-C. (1996) · Springer eBooks · doi:10.1007/978-1-4615-5873-6_20 · Cited by 78
Easton, J. B., Wei, T., Lahti, J. M., & Kidd, V. J. (1998) · PubMed · Cited by 78
Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness.
Huuhtanen, R., BLOMQVIST, C. P., Böhling, T., Wiklund, T. A., Tukiainen, E. J., Virolainen, M. J., Tribukait, B., & Andersson, L. C. (1999) · PubMed · Cited by 78
Cellular effects of purvalanol A: A specific inhibitor of cyclin‐dependent kinase activities
Villerbu, N., Gaben, A., Redeuilh, G., & Mešter, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.10125 · Cited by 75
Joshi, K., Rathos, M. J., Mahajan, P., Wagh, V., Shenoy, S. S., Bhatia, D. R., Chile, S., Sivakumar, M., Maier, A., Fiebig, H., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0614 · Cited by 74
A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors
Villoutreix, B. O., Labbé, C. M., Lagorce, D., Laconde, G., & Spérandio, O. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651571 · Cited by 74
Koutsami, M., Tsantoulis, P. K., Kouloukoussa, M., Apostolopoulou, K., Pateras, I. S., Spartinou, Z., Drougou, A., Evangelou, K., Kittas, C. N., Bártková, J., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2005 · Cited by 73
Mutoh, M., Lung, F. ‐. T., Long, Y. Q., Roller, P. P., Sikorski, R. S., & O'Connor, P. M. (1999) · PubMed · doi:10.11501/3170955 · Cited by 72
Li, S., MacLachlan, T. K., Luca, A. D., Claudio, P. P., Condorelli, G., & Giordano, A. (1995) · PubMed · Cited by 72
Pennati, M., Campbell, A. J., Curto, M., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0022 · Cited by 72
Mendoza, N., Fong, S., Marsters, J., Koeppen, H., SCHWALL, R. H., & Wickramasinghe, D. (2003) · PubMed · Cited by 71
Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology
Zhang, C., Lopez, M. S., Dar, A. C., LaDow, E., Finkbeiner, S. M., Yun, C., Eck, M. J., & Shokat, K. M. (2013) · ACS Chemical Biology · doi:10.1021/cb400376p · Cited by 70
Duan, Z., Zhang, J., Choy, E., Harmon, D. C., Liu, X., Nielsen, P., Mankin, H. J., Gray, N. S., & Hornicek, F. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1157 · Cited by 69
Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma
Abdullah, C., Wang, X., & Becker, D. (2011) · Cell Cycle · doi:10.4161/cc.10.6.15079 · Cited by 68
Kubo, A., Nakagawa, K., Varma, R. K., Conrad, N. K., Cheng, J. Q., Lee, W. C., Testa, J. R., Johnson, B. E., Kaye, F. J., & Kelley, M. J. (1999) · PubMed · Cited by 68
Phosphorylation of human DNMT1: Implication of cyclin-dependent kinases
Lavoie, G., & St‐Pierre, Y. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.115 · Cited by 68
Molenaar, J. J., Köster, J., Ebus, M. E., Sluis, P. V., Westerhout, E. M., Preter, K. D., Gisselsson, D., Øra, I., Speleman, F., Caron, H. N., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20926 · Cited by 67
Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation
Gondeau, C., Gerbal‐Chaloin, S., Bello, P. A., Aldrian, G., Morris, M. C., & Divita, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413690200 · Cited by 67
Self-citationKinetic Mechanism of Activation of the Cdk2/Cyclin A Complex
Morris, M. C., Gondeau, C., Tainer, J. A., & Divita, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107890200 · Cited by 67
Self-citationZheleva, D. I., McInnes, C., Gavine, A. ‐., Zhelev, N., Fischer, P. M., & Lane, D. P. (2002) · Journal of Peptide Research · doi:10.1034/j.1399-3011.2002.21014.x · Cited by 67
Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix
Cheung, T. H., Yu, M. M. Y., Lo, K. W. K., Yim, S. F., Chung, T. K. H., & Wong, Y. F. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00457-8 · Cited by 67
Role of cdk5 in the Pathogenesis of Alzheimer’s Disease
Lau, L., & Ahlijanian, M. K. (2003) · Neurosignals · doi:10.1159/000074622 · Cited by 65
Combined kinase inhibition modulates parkin inactivation
de la Torre, E. R., Luzón-Toro, B., Forte‐Lago, I., Mínguez‐Castellanos, A., Ferrer, I., & Hilfiker, S. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn407 · Cited by 65
Tomashevski, A., Webster, D. R., Grammas, P., Gorospe, M., & Kruman, I. I. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2009.221 · Cited by 62
Siemeister, G., Luecking, U., Wagner, C., Detjen, K. M., Coy, C. M., & Bosslet, K. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.003 · Cited by 62
Cdk5 Nuclear Localization Is p27-dependent in Nerve Cells
Zhang, J., Li, H., & Herrup, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.068262 · Cited by 61
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation
Bellan, C., Falco, G. D., Lazzi, S., Micheli, P., Vicidomini, S., Schürfeld, K., Amato, T., Palumbo, A., Bagella, L., Sabattini, E., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1588 · Cited by 61
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis
Liu, J., Wang, X., Huang, B., et al. (2010) · Medical Oncology · doi:10.1007/s12032-010-9510-7 · Cited by 61
Cyclin-Dependent Kinase 5 in Amyotrophic Lateral Sclerosis
Nguyen, M. D., & Julien, J. (2003) · Neurosignals · doi:10.1159/000074623 · Cited by 61
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
Lockwood, W. W., Stack, D., Morris, T., Grehan, D., O’Keane, C., Stewart, G. L., Cumiskey, J., Lam, W. L., Squire, J. A., Thomas, D. M., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.020 · Cited by 60
Novel splice variants of cyclin E with altered substrate specificity
Porter, D. C., & Keyomarsi, K. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.23.e101 · Cited by 59
Flavopiridol in the treatment of chronic lymphocytic leukemia
Christian, B. A., Grever, M. R., Byrd, J. C., & Lin, T. S. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282efb9da · Cited by 58
Andrews, M. J. I., McInnes, C., Kontopidis, G. A., et al. (2004) · Organic & Biomolecular Chemistry · doi:10.1039/b409157d · Cited by 58
Zhang, C., ELKAHLOUN, A. G., Robertson, M., Gills, J. J., Tsurutani, J., Shih, J. H., Fukuoka, J., Hollander, M. C., Harris, C. C., Travis, W. D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023849 · Cited by 57
Dobashi, Y., Goto, A., Fukayama, M., Abe, A., & Ooi, A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20167 · Cited by 57
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells
Jia, B., Choy, E., Cote, G. M., Harmon, D. C., Ye, S., Kan, Q., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.040 · Cited by 57
Sotillo, R., Renner, O., Dubus, P. R., Ruíz-Cabello, J., Martín‐Caballero, J., Barbacid, M., Carnero, A., & Malumbres, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4195 · Cited by 56
Dai, L., Liu, Y., Liu, J., Wen, X., Xu, Z., Wang, Z., Sun, H., Tang, S., Maguire, A. R., Quan, J., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.025 · Cited by 56
Squires, M. S., Cooke, L. S., Lock, V., Qi, W., Lewis, E. J., Thompson, N. T., Lyons, J. F., & Mahadevan, D. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1071 · Cited by 56
Canela-Canela, N., Orzáez, M., Fucho, R., Mateo, F., Gallego, R. G., Pineda‐Lucena, A., Bachs, O., & Pérez‐Payá, E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603511200 · Cited by 55
Lam, F., Abbas, A. Y., Shao, H., Teo, T., Adams, J., Li, P., Bradshaw, T. D., Fischer, P. M., Walsby, E. J., Pepper, C. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2296 · Cited by 55
Husdal, A., Bukholm, G., & Bukholm, I. R. K. (2006) · Analytical Cellular Pathology · doi:10.1155/2006/721919 · Cited by 54
Emerging roles of Cdk8 in cell cycle control
Szilágyi, Z., & Gustafsson, C. M. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.04.010 · Cited by 53
Structural dissection of cyclin dependent kinases regulation and protein recognition properties
Lolli, G. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11195 · Cited by 53
Lim (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.948 · Cited by 53
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro
Peterson, D. W., Ando, D. M., Taketa, D. A., Zhou, H., Dahlquist, F. W., & Lew, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912718107 · Cited by 53
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells
Yu, J., Zhong, X., Zhang, W., Wang, Z., Dong, Q., Tai, S., Li, H., & Cui, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1617 · Cited by 52
Wingate, H. F., Puskás, Á., Duong, M. T., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.7.8119 · Cited by 51
Tumor-suppressive effects of CDK8 in endometrial cancer cells
Gu, W., Wang, C., Li, W., Hsu, F.-N., Tian, L., Zhou, J., Yuan, C., Xie, X.-J., Jiang, T., Addya, S., et al. (2013) · Cell Cycle · doi:10.4161/cc.24003 · Cited by 51
SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2
Moshinsky, D. J., Bellamacina, C. R., Boisvert, D. C., Huang, P. H., Hui, T., Jancarik, J., Kim, S., & Rice, A. G. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.114 · Cited by 51
Falco, G. D., Bellan, C., D’Amuri, A., Angeloni, G., Leucci, E., Giordano, A., & Leoncini, L. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1497 · Cited by 50
A Chrysin Derivative Suppresses Skin Cancer Growth by Inhibiting Cyclin-dependent Kinases
Liu, H., Liu, K., Huang, Z., Park, C. M., Thimmegowda, N. R., Jang, J., Ryoo, I., He, L., Kim, S.-O., Oi, N., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.464669 · Cited by 50
Neuronal Cdc2-like kinases: Neuron-specific forms of Cdk5
Lee, K.-Y., Qi, R. Z., Yu, Y. P., & Wang, J. H.-C. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(97)00048-4 · Cited by 49
Revving the Throttle on an Oncogene: CDK8 Takes the Driver Seat
Firestein, R., & Hahn, W. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1704 · Cited by 49
Zhao, M. Y., Auerbach, A., D'Costa, A. M., Rapoport, A. P., Burger, A. M., Sausville, E. A., Stass, S. A., Jiang, F., Sands, A. M., Aguilera, N. S. I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1543 · Cited by 49
Molecular alterations associated with cyclin d1 overexpression in endometrial cancer
Moreno‐Bueno, G., Rodríguez, S., Sánchez‐Estévez, C., Marcos, R., Hardisson, D., Cigudosa, J. C., & Palacios, J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20130 · Cited by 49
Blockbuster dreams for Pfizer's CDK inhibitor
Guha, M. (2013) · Nature Biotechnology · doi:10.1038/nbt0313-187a · Cited by 49
Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells
Catania, A., Urban, S., Yan, E., Hao, C., Barron, G., & Allalunis‐Turner, J. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.2.89 · Cited by 48
Romano, G. (2013) · ISRN Oncology · doi:10.1155/2013/305371 · Cited by 47
Bagella, L., Sun, A., Tonini, T., Abbadessa, G., Cottone, G., Paggi, M. G., Luca, A. D., Claudio, P. P., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209987 · Cited by 47
ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
Abate, A. A., Pentimalli, F., Esposito, L., & Giordano, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.798641 · Cited by 47
Wołowiec, D., Benchaïb, M., Pernas, P., Deviller, P., Souchier, C., Rimokh, R., Felman, P., Bryon, P. A., & Ffrench, M. (1995) · PubMed · Cited by 46
Clinical and biological significance of Cdk10 in hepatocellular carcinoma
Zhong, X., Xu, X., Yu, J., Jiang, G., Yu, Y., Tai, S., Wang, Z., & Cui, Y. (2012) · Gene · doi:10.1016/j.gene.2012.01.022 · Cited by 44
Ekberg, J., Holm, C., Jalili, S., Richter, J., Anagnostaki, L., Landberg, G., & Persson, J. L. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00473.x · Cited by 44
Role of CDK8 and β-catenin in colorectal adenocarcinoma
Lim (2010) · Oncology Reports · doi:10.3892/or_00000858 · Cited by 43
p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity
Zhang, L., Liu, W., Szumlinski, K. K., & Lew, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212914109 · Cited by 41
Abramson, V. G., Troxel, A. B., Feldman, M. D., Mies, C., Wang, Y., Sherman, L. S., McNally, S., Diehl, J. A., & DeMichele, A. M. (2010) · PubMed · Cited by 39
An Inhibitor’s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States
Echalier, A., Hole, A. J., Lolli, G., Endicott, J., & Noble, M. E. M. (2014) · ACS Chemical Biology · doi:10.1021/cb500135f · Cited by 39
Regulatory functions of Cdk9 and of cyclin T1 in HIV Tat transactivation pathway gene expression
Romano, G., Kasten, M. M., Falco, G. D., Micheli, P., Khalili, K., & Giordano, A. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19991201)75:3<357::aid-jcb1>3.0.co;2-k · Cited by 39
Tudhope, S. J., Wang, C.-C., Petrie, J. L., Potts, L. D., Malcomson, F. C., Kieswich, J. E., Yaqoob, M. M., Arden, C., Hampson, L. J., & Agius, L. (2011) · Diabetes · doi:10.2337/db11-0870 · Cited by 39
Roscovitine blocks leukocyte extravasation by inhibition of cyclin‐dependent kinases 5 and 9
Berberich, N., Uhl, B., Joore, J., Schmerwitz, U. K., Mayer, B. A., Reichel, C. A., Krombach, F., Zahler, S., Vollmar, A. M., & Fürst, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01309.x · Cited by 38
Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
Park, S., Lee, J., Do, I., Jang, J., Rho, K., Ahn, S., Lira, M., Kim, S. J., Kim, K., Mao, M., et al. (2014) · Scientific Reports · doi:10.1038/srep03623 · Cited by 38
Protein-Protein Interactions: Lessons Learned
Sharma, S., Ramsey, T. M., & Bair, K. W. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354191 · Cited by 38
Scholz, A., Wagner, K. G., Welzel, M., Remlinger, F., Wiedenmann, B., Siemeister, G., Rosewicz, S., & Detjen, K. M. (2008) · Gut · doi:10.1136/gut.2007.146415 · Cited by 38
Fluorescent biosensors for high throughput screening of protein kinase inhibitors
Prével, C., Pellerano, M., Van, T. N. N., & Morris, M. C. (2013) · Biotechnology Journal · doi:10.1002/biot.201300196 · Cited by 38
Self-citationDemange, L., Abdellah, F. N., Lozach, O., Ferandin, Y., Gresh, N., Meijer, L., & Galons, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.141 · Cited by 37
Kato, G., & Maeda, S. (1999) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022540 · Cited by 37
Li, R., An, S., Chen, Z. H., Zhang, G.-C., Zhu, J.-Q., Nie, Q., Xie, Z., Guo, A., Mok, T. S. K., & Wu, Y.-L. L. C. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.05.008 · Cited by 37
Harwell, R. M., Mull, B. B., Porter, D. C., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313407200 · Cited by 36
Cdk1 interplays with Oct4 to repress differentiation of embryonic stem cells into trophectoderm
Li, L., Wang, J., Hou, J., Wu, Z., Zhuang, Y., Lu, M., Zhang, Y., Zhou, X., Li, Z., Xiao, W., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.10.030 · Cited by 36
Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors
Rosania, G. R., & Chang, Y. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.2.215 · Cited by 36
Neuronal Cdc2-like kinase: from cell cycle to neuronal function
Tang, D., Matsuura, I., Wang, J. H.-C., Lee, K.-Y., & Qi, R. Z. (1996) · Biochemistry and Cell Biology · doi:10.1139/o96-046 · Cited by 35
Corbel, C., Wang, Q., Bousserouel, H., Hamdi, A., Zhang, B., Lozach, O., Ferandin, Y., Tan, V. B. C., Guéritte, F., Colas, P., et al. (2011) · Biotechnology Journal · doi:10.1002/biot.201100138 · Cited by 35
Su, W. T., Alaminos, M., Mora, J., Cheung, N. V., LaQuaglia, M. P., & Gerald, W. L. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.02.009 · Cited by 35
Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients
Levacque, Z., Rosales, J. L., & Lee, K. (2012) · Cell Cycle · doi:10.4161/cc.21886 · Cited by 33
Vincent‐Fabert, C., Fiancette, R., Rouaud, P., Baudet, C., Truffinet, V., Magnone, V., Guillaudeau, A., Cogné, M., Dubus, P. R., & Denizot, Y. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.004 · Cited by 33
Exploiting structural principles to design cyclin-dependent kinase inhibitors
Noble, M. E. M., Barrett, P. J., Endicott, J., Johnson, L., McDonnell, J., Robertson, G., & Zawaira, A. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.019 · Cited by 31
Miyagaki, H., Yamasaki, M., Miyata, H., Takahashi, T., Kurokawa, Y., Nakajima, K., Takiguchi, S., Fujiwara, Y., Ishii, H., Tanaka, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.35 · Cited by 31
Diab, S., Eckhardt, S. G., Tan, A. R., Frenette, G., Gore, L., DePinto, W., Grippo, J. F., DeMario, M., Mikulski, S. M., & Papadimitrakopoulou, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3528 · Cited by 29
ATP‐Noncompetitive Inhibitors of CDK–Cyclin Complexes
Orzáez, M., Gortat, A., Mondragón, L., Bachs, O., & Pérez‐Payá, E. (2008) · ChemMedChem · doi:10.1002/cmdc.200800185 · Cited by 29
Simone, C., & Giordano, A. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402008 · Cited by 29
Bhonde, M., Hanski, M., Magrini, R., Moorthy, N. D., Müller, A., Sausville, E. A., Kohno, K., Wiegand, P., Daniel, P. T., Zeitz, M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207842 · Cited by 28
An in silico approach for the discovery of CDK5/p25 interaction inhibitors
Zhang, B., Corbel, C., Guéritte, F., Couturier, C., Bach, S., & Tan, V. B. C. (2011) · Biotechnology Journal · doi:10.1002/biot.201100139 · Cited by 27
Warenius, H. M., Kilburn, J., Essex, J. W., Maurer, R. I., Blaydes, J. P., Agarwala, U., & Seabra, L. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-72 · Cited by 27
2-Aminoquinazoline inhibitors of cyclin-dependent kinases
Bathini, Y., Singh, I., Harvey, P. J., Keller, P. R., Singh, R., Micetich, R. G., Fry, D. W., Dobrusin, E. M., & Toogood, P. L. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.131 · Cited by 26
Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice
Chandramouli, A., Shi, J., Feng, Y., Holubec, H., Shañas, R., Bhattacharyya, A. K., Zheng, W., & Nelson, M. A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm066 · Cited by 25
Cooperativity ofCdk4R24CandRasin melanoma development
Chawla, R., Procknow, J. A., Tantravahi, R. V., Khurana, J., Litvin, J., & Reddy, E. P. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12632 · Cited by 24
Kontopidis, G. A., Andrews, M. J. I., McInnes, C., Plater, A., Innes, L., Renachowski, S., Cowan, A., & Fischer, P. M. (2009) · ChemMedChem · doi:10.1002/cmdc.200900093 · Cited by 24
Liu, S., Bolger, J. K., Kirkland, L. O., Premnath, P. N., & McInnes, C. (2010) · ACS Chemical Biology · doi:10.1021/cb1001262 · Cited by 23
Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma
Nar, A., Özen, Ö., Tütüncü, N. B., & Demirhan, B. (2011) · Medical Oncology · doi:10.1007/s12032-010-9800-0 · Cited by 23
Prével, C., Kurzawa, L., Van, T. N. N., & Morris, M. C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.003 · Cited by 23
Self-citationShapiro, G. I., Bannerji, R., Small, K. A., Black, S., Statkevich, P., Abutarif, M. A., Moseley, J. L., Yao, S., Takimoto, C. H. M., & Mita, M. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3532 · Cited by 23
Cdk1 phosphorylation of the kinetochore protein Nsk1 prevents error-prone chromosome segregation
Chen, J., Lu, L. X., Ohi, M. D., Creamer, K. M., English, C. A., Partridge, J. F., Ohi, R., & Gould, K. L. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201105074 · Cited by 22
Brown, A. P., Courtney, C. L., Criswell, K. A., Holliman, C. L., Evering, W., & Jessen, B. A. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0771-1 · Cited by 21
Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas
Seong, J., Chung, E. J., Kim, H., Kim, G. E., Kim, N. K., Sohn, S. K., Min, J. S., & Suh, C. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00302-8 · Cited by 21
Santala, S., Talvensaari‐Mattila, A., Soini, Y., Honkavuori-Toivola, M., & Santala, M. (2014) · Tumor Biology · doi:10.1007/s13277-014-1703-9 · Cited by 21
Corsino, P. E., Horenstein, N. A., Ostrov, D. A., Rowe, T. C., Law, M. E., Barrett, A., Aslanidi, G., Cress, W. D., & Law, B. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.055251 · Cited by 21
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
Metadata
- Authors
- Peyressatre, M., Prével, C., Pellerano, M., & Morris, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-01-23
- Volume
- 7
- Issue
- 1
- Pages
- 179-237
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2143238584
- Cited by
- 344
- References
- 405
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.